These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23327959)

  • 61. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.
    Bordon V; Padalko E; Benoit Y; Dhooge C; Laureys G
    Pediatr Transplant; 2012 Mar; 16(2):144-50. PubMed ID: 22288846
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.
    Faye A; Quartier P; Reguerre Y; Lutz P; Carret AS; Dehée A; Rohrlich P; Peuchmaur M; Matthieu-Boué A; Fischer A; Vilmer E
    Br J Haematol; 2001 Oct; 115(1):112-8. PubMed ID: 11722420
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.
    Liu QF; Ling YW; Fan ZP; Jiang QL; Sun J; Wu XL; Zhao J; Wei Q; Zhang Y; Yu GP; Wu MQ; Feng R
    Transpl Infect Dis; 2013 Aug; 15(4):379-92. PubMed ID: 23692640
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation.
    Weber T; Wickenhauser C; Monecke A; Gläser C; Stadler M; Desole M; Ligeti K; Behrmann C; Müller-Tidow C; Müller LP
    Transpl Infect Dis; 2014 Dec; 16(6):988-92. PubMed ID: 25179757
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.
    Jain T; Kosiorek HE; Grys TE; Kung ST; Shah VS; Betcher JA; Slack JL; Leis JF; Khera N; Noel P; Palmer JM; Sproat LZ
    Leuk Lymphoma; 2019 Jan; 60(1):110-117. PubMed ID: 29979906
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation.
    De Pasquale MD; Mastronuzzi A; De Vito R; Cometa A; Inserra A; Russo C; De Ioris MA; Locatelli F
    Pediatrics; 2012 Jan; 129(1):e189-94. PubMed ID: 22144701
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation.
    Tanaka T; Takizawa J; Miyakoshi S; Kozakai T; Fuse K; Shibasaki Y; Moriyama M; Ohshima K; Toba K; Furukawa T; Sone H; Masuko M
    Intern Med; 2014; 53(18):2115-9. PubMed ID: 25224199
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
    Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
    Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
    Gruhn B; Meerbach A; Häfer R; Zell R; Wutzler P; Zintl F
    Bone Marrow Transplant; 2003 Jun; 31(11):1023-5. PubMed ID: 12774054
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
    Ruf S; Moser O; Wössmann W; Kreyenberg H; Wagner HJ
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):50-4. PubMed ID: 21178708
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
    Dumas PY; Ruggeri A; Robin M; Crotta A; Abraham J; Forcade E; Bay JO; Michallet M; Bertrand Y; Socié G; Ionescu I; Gluckman E; Milpied N; Rocha V
    Bone Marrow Transplant; 2013 Feb; 48(2):253-6. PubMed ID: 22773124
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.